Progress has been made in the treatment of neuroblastoma

researchers at the University of Seville and the Institute of Biomedical Research in Seville, Spain, recently determined that a protein called CD44 can identify cancer stem cell populations that cause neuroblastoma invasiveness and low survival. The paper was published in the open source journal E Biomedical. Neuroblastoma is a type of cancer that mainly affects children between 2 and 3 years of age.
"We believe that cd44 proteins promote aggressive behavior of cancer stem cells that cause tumor growth, recurrence, and metastasis." We believe that by interrupting the function of the cell's adhesion molecule, we can provide new treatment options to eliminate these cells, thereby improving the treatment of neuroblastoma. Ricardo Pardal, the study's communications author, said.
researchers used tumor samples from patients with neuroblastoma at the University Hospital of Vergen del Rocio in Seville and transcriptional group analysis of tumor samples from patients to study the prognosis of patients with cd44 high expression. They adhesion, invasion and proliferation experiments on isolated CD44 high-expression neuroblastoma cells, and assessed the potential of self-renewal and differentiation of tumor cells.
found that high expression of CD44 in neuroblastoma was associated with low survival in patients. CD44 is expressed in cell groups with neural stem cell-like characteristics and has the ability to produce pluripotent, undifferentiated tumor balls in culture, which are more invasive and proliferating in inosotrophy. Moreover, CD44-positive cells obtained from tumors have higher tumor-like and metastasis, and high-frequency invasive neuroblast tumors can occur after transplantation.
"Our results do not improve prevention of the disease, but they can improve the diagnosis of the disease and affect our ability to improve the type of treatment required in the subgroups of neuroblastoma patients," he said. Therefore, these findings should at least contribute to the diagnosis and treatment of patients with high levels of CD44 expression in tumors. Pardal said. (Source: Lu Yi, China Science Journal)
related paper information: